Information Provided By: 
Fly News Breaks for May 3, 2016
ALNY
May 3, 2016 | 07:25 EDT
Leerink analyst Michael Schmidt lowered his price target for Alnylam to $107 from $120 to account for higher research and development expenses than expected. The analyst also removed his highly probability-adjusted ALN-CC5 estimates from his model, after mixed Phase 1 data. Schmidt says Alnylam remains well capitalized and ended the year with $1B in cash and restricted marketable securities. The analyst reiterates an Outperform rating on the shares.
News For ALNY From the Last 2 Days
ALNY
Apr 23, 2024 | 07:17 EDT
ProQR Therapeutics (PRQR) announced the Annual General Meeting, AGM, of Shareholders will take place on Wednesday, May 22, 2024 at the offices of Allen & Overy LLP, in Amsterdam, the Netherlands. As part of the AGM, Martin Maier, PhD, is nominated for appointment as a non-executive Board Member for a period of four years. Dr. Maier is Senior Vice President Research heading the Oncology group at Alnylam Pharmaceuticals (ALNY).
